Clinical Trial Update: Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated stem cell mobilization using AMD3100 (plerixafor) plus G-CSF in patients with non-Hodgkin lymphoma and multiple myeloma; the study has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Mozobil (plerixafor)
• Neupogen (Filgrastim)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2010-11-24